August 31, 2020
Pharmaceutical giant AstraZeneca (Tii:AZN) says it has held no discussions with the U.S. government about emergency authorization for the COVID-19 vaccine it is manufacturing. That vaccine is still undergoing late stage human clinical trials in several sites around the world, including in the U.K. and the U.S., making a rapid approval under the criteria the U.S. Food and Drug Administration has established so far a long shot.
Palantir (Tii:PLTR), the data analytics company whose work on counter-terrorism has made it one of the Silicon Valley’s most controversial tech concerns, has sought to draw a clear line between its own business and what it dismissed as the “idiosyncrasies and excesses” of the rest of the valley, as it announced plans for a stock market listing.
Dick’s Sporting Goods (Tii:DKS) reported eye-popping quarterly earnings and sales growth Wednesday, saying consumers flocked to its website for hiking gear, kayaks, weights and workout clothes to stay busy during the coronavirus crisis.
Facebook (Tii:FB) on Wednesday acknowledged that Apple’s (Tii:AAPL) upcoming iOS 14 could lead to a more than 50% drop in its Audience Network advertising business. Facebook said its apps on iOS 14 will not collect IDFA, which is a unique device ID number that allows advertisers to better target ads and estimate their effectiveness.
Abbott Laboratories (Tii:ABT) said on Wednesday it won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results within 15 minutes and will sell for $5. The portable test is about the size of a credit card, requires no additional equipment to operate, and can be conducted using a less invasive nasal swab than traditional lab tests, Abbott executives said on a call with reporters.